Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts

  • Authors:
    • Shiva S. Forootan
    • Zheng Z. Bao
    • Farzad S. Forootan
    • Laleh Kamalian
    • Yu Zhang
    • Alix Bee
    • Christopher S. Foster
    • Youqiang Ke
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ijo_00000476
  • Pages: 69-76
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The gene FABP5 encodes cutaneous fatty acid binding protein (C-FABP) that is up-regulated in prostate cancer where it acts as a putative oncogene. To test the hypothesis that siRNA to FABP5 delivered to the external environment of a prostate cancer would reduce the level of C-FABP in vivo, experiments were established whereby siRNA to FABP5 suspended in atelocollagen was injected around tumour masses produced by PC-3M cells in Balb/c nude mice and compared with the effect of non-specific scrambled siRNA in atelocollagen. At autopsy, the average size of tumours from the groups treated with 10 and 15 µM siRNA in atelocollagen was significantly (p=0.02) reduced by more than 3-fold, when compared to the controls. In contrast, when compared to the tumours produced by the group treated with scrambled siRNA, treatment with 10 µM FABP5 siRNA in buffer and 1 or 5 µM siRNA in atelocollagen did not produce significant differences. Although the dosage of 15 µM siRNA produced a greater reduction in tumour sizes when compared with 10 µM, this difference was not significant (p=0.9). Immunohistochemistry and Western blotting revealed that the levels of C-FABP expression in tumours from mice treated with 10 and 15 µM dosages were lower than those from the other groups. These data demonstrate that FABP5 siRNA delivered by atelocollagen to the external environment surrounding a tumour mass can effectively inhibit prostate cancer cell growth in nude mice when administered in a dose-dependent manner at concentrations of >10 µM.

Related Articles

Journal Cover

January 2010
Volume 36 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Forootan, S.S., Bao, Z.Z., Forootan, F.S., Kamalian, L., Zhang, Y., Bee, A. ... Ke, Y. (2010). Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts. International Journal of Oncology, 36, 69-76. https://doi.org/10.3892/ijo_00000476
MLA
Forootan, S. S., Bao, Z. Z., Forootan, F. S., Kamalian, L., Zhang, Y., Bee, A., Foster, C. S., Ke, Y."Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts". International Journal of Oncology 36.1 (2010): 69-76.
Chicago
Forootan, S. S., Bao, Z. Z., Forootan, F. S., Kamalian, L., Zhang, Y., Bee, A., Foster, C. S., Ke, Y."Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts". International Journal of Oncology 36, no. 1 (2010): 69-76. https://doi.org/10.3892/ijo_00000476